KEVEYIS
LOE Approachingdichlorphenamide
NDAORALTABLET
Approved
Jul 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
KEVEYIS (dichlorphenamide) is carbonic anhydrase inhibitors [moa]. Approved for primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, related variants (). First approved in 1958.
Drug data last refreshed 14h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEVEYIS (dichlorphenamide) is an oral carbonic anhydrase inhibitor approved in 1958 for treatment of primary hyperkalemic and hypokalemic periodic paralysis. It works by inhibiting carbonic anhydrase to modulate ion channel dysfunction underlying these rare genetic muscle disorders. This is a niche orphan therapy targeting a small, well-defined patient population with severe episodic muscle weakness.
$21MPart D
LOE ApproachingThis vintage small-molecule asset faces patent expiration pressure with modest Part D utilization, suggesting a mature niche market with limited growth runway and smaller commercial support infrastructure.
Mechanism of Action
Carbonic Anhydrase Inhibitors
Pharmacologic Class:
Carbonic Anhydrase Inhibitor
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.